CAJ | 학술논문

目的：观察重组白介素(rIL-2)与顺铂(DDP)胸腹腔注入治疗恶性胸腹水的疗效。方法：对45例恶性胸腹水患者应用rIL-2与DDP胸腹腔注入；对照组40例患者采用DDP做胸腹腔注入以做比较。结果：治疗组治疗恶性胸腹水总有效率89％，其中胸水有效率达90％，腹水有效率达88％。DDP对照组治疗恶性胸腹水总有效率70％，其中胸水有效率达72.2％，腹水有效率达68.2％。结论：rIL-2与DDP联合应用治疗恶性胸腹水有显著的协同作用(χ2=4.72，P＜0.05)，毒副反应小，见效快，能及时减轻患者的痛苦，是安全有效的方法。
목적：관찰중조백개소(rIL-2)여순박(DDP)흉복강주입치료악성흉복수적료효。방법：대45례악성흉복수환자응용rIL-2여DDP흉복강주입；대조조40례환자채용DDP주흉복강주입이주비교。결과：치료조치료악성흉복수총유효솔89％，기중흉수유효솔체90％，복수유효솔체88％。DDP대조조치료악성흉복수총유효솔70％，기중흉수유효솔체72.2％，복수유효솔체68.2％。결론：rIL-2여DDP연합응용치료악성흉복수유현저적협동작용(χ2=4.72，P＜0.05)，독부반응소，견효쾌，능급시감경환자적통고，시안전유효적방법。
Objective: To boserve therapeutic effectiveness of cisplatin plus interleukin-l in malignant hydrothorax and as-cites. Methos: In experimental group, 45 cases were injected interleukin-Ⅱ and cisplation into thoracic cavity or abdominalcavity once a week, 3-6 weeks as one cylce. As a control group,40 cases were injected cisplation alone in the same way. Re-sults: The total effective rate in experimental group was 89% ,about 90% in hydrothorax,89% in ascites. The rates in controlgroup were 70%, 72.2 % and 68.2 %, respectively. Conclusion: Interleukin-Ⅱ and cisplatin were synergistic in treating ma-lignatn hydrothorax and ascites. Statistic management was significant(χ2=4.72, P＜0.05). It has practical value of extendingto clinical appliction.